[Renal impairment induced by nonselective prostaglandin inhibitor]

Ita Samarija1, Ljubica Bubić-Filipi

  • 1Department of Pharmacology, School of Pharmacy and Biochemistry, University of Zagreb, Croatia. itas@pharma.hr

Insights

Nonsteroidal antirheumatics like diclofenac can harm kidney function by inhibiting prostaglandins. This study shows diclofenac alters proximal tubule cell potential and glucose transport, especially at higher doses.

Area of Science:

  • Nephrology
  • Pharmacology
  • Physiology

Context:

  • Kidney function is vital for fluid balance but kidneys are susceptible to drug-induced damage.
  • Nonsteroidal antirheumatics (NSARs) can cause nephrotoxicity by inhibiting prostaglandin synthesis.
  • Prostaglandins are crucial for maintaining renal blood flow and tubular function.

Purpose:

  • To investigate the effects of prostaglandin E2 (PGE2) and Na-diclofenac on proximal tubule cellular potential and glucose transport.
  • To evaluate the impact of prostaglandin inhibition on renal transport processes using electrophysiological studies in experimental animals.

Summary:

  • Prostaglandin E2 (PGE2) stimulates sodium and glucose cotransport in proximal tubules without altering cell potential.
  • Na-diclofenac, a prostaglandin synthesis inhibitor, causes concentration-dependent depolarization of proximal tubule cells.
  • High concentrations of diclofenac lead to nonspecific effects and permanent depolarization, impairing ion and substrate cotransport.

Impact:

  • Findings provide insights into the nephrotoxic mechanisms of nonsteroidal antirheumatics (NSARs).
  • Results can aid specialists in managing patients with renal dysfunction or kidney disease.
  • Contributes to the rational use of analgesics and recognition of risk factors in vulnerable populations, particularly the elderly.

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...